Ethics and Economics最新文献_第5页

Cost-utility analysis of a Home-based disease management intervention for patients with severe COPD in the COMET study. COMET研究中重症COPD患者家庭疾病管理干预的成本-效用分析

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3162

D. Granados, J. Bourbeau, I. Durand-zaleski, S. Roze, R. Kessler

引用次数: 1

Prospective study of last minute cancellations of thoracic surgery operations and preventive measures 最后一分钟取消胸外科手术及预防措施的前瞻性研究

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3166

Ç. Tezel, Onur Derdiyok, S. Evman, Serda Kanbur, M. Demir, L. Alpay, V. Baysungur

引用次数: 1

Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD 单吸入器三联疗法与ICS/LABA治疗COPD的成本效益比较

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3154

Alan A Martin, D. Shah, E. Goodall, M. Schroeder, N. Risebrough, K. Ndirangu, A. Ismaila

{"title":"Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD","authors":"Alan A Martin, D. Shah, E. Goodall, M. Schroeder, N. Risebrough, K. Ndirangu, A. Ismaila","doi":"10.1183/13993003.CONGRESS-2018.PA3154","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3154","url":null,"abstract":"Background: IMPACT (InforMing the PAthway of COPD Treatment, NCT02164513), showed superior exacerbation reduction and lung function improvement with single inhaler, once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/22μg vs once-daily FF/VI 100/22μg, for patients with moderate/severe COPD. Objectives: The cost-effectiveness of FF/UMEC/VI vs FF/VI was assessed, from a Canadian public payer perspective. Methods: A validated linked risk equation model (Briggs, Med Decis Making 37;4 2017), which predicts COPD disease progression, associated healthcare costs and health outcomes, was populated with baseline characteristics, efficacy and medication use from IMPACT. Canadian healthcare resource unit costs and drug costs were applied, with future costs and health outcomes discounted at 1.5% annually. Analysis was probabilistic, with a lifetime horizon and outputs including exacerbation rates, costs (2017 CAD), quality-adjusted life years (QALYs) gained and incremental cost effectiveness ratio (ICER) per QALY. Results: Compared with FF/VI, FF/UMEC/VI treatment resulted in fewer moderate and severe exacerbations (10.52 and 3.38 vs 11.13 and 3.48), mean (95% CI) incremental costs and QALYs of $2,598 ($2,010, $3,268) and 0.13 (0.09, 0.18), and an ICER of $19,649 per QALY ($15,406, $26,454). The probability of FF/UMEC/VI being cost-effective vs FF/VI was 100% at a willingness-to-pay threshold of $50,000 per QALY. Results were most sensitive to time horizon, and efficacy of treatment post-discontinuation. Conclusions: FF/UMEC/VI was predicted to improve health outcomes and to be a cost-effective option for treatment of moderate/severe COPD compared with FF/VI, in Canada.","PeriodicalId":243267,"journal":{"name":"Ethics and Economics","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130821562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality indicators in pleural pathology 胸膜病理质量指标

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3165

Herminia Ortiz Mayoral, R. López, R. M. Íñiguez, N. Santamaría, María Teresa Río Ramírez, I. A. García, B. Steen, Mercedes Izquierdo Patrón, Beatriz Morales Chacón

引用次数: 0

Identifying predictors of healthcare utilization and costs in COPD patients over 18 months: first longitudinal results of the COSYCONET cohort 确定COPD患者18个月以上医疗保健利用和成本的预测因素:COSYCONET队列的首次纵向结果

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3152

D. Byng, J. Lutter, R. Holle, R. Jörres, A. Karch, S. Karrasch, H. Schulz, C. Vogelmeier, M. Wacker

{"title":"Identifying predictors of healthcare utilization and costs in COPD patients over 18 months: first longitudinal results of the COSYCONET cohort","authors":"D. Byng, J. Lutter, R. Holle, R. Jörres, A. Karch, S. Karrasch, H. Schulz, C. Vogelmeier, M. Wacker","doi":"10.1183/13993003.CONGRESS-2018.PA3152","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3152","url":null,"abstract":"Background: COPD is associated with excess healthcare utilization and represents high costs to health systems. This study reports trends in healthcare utilization and healthcare costs and identifies predictors of cost changes. Methods: 1904 COPD patients participated in the baseline and 18 months follow-up visit of the German COSYCONET cohort study. Costs were calculated from a societal perspective. Predictors of changes in direct costs at the follow up visit were identified by gamma regression models using baseline information on GOLD grade, age, sex, education, BMI, smoking status, comorbidity count, years since COPD diagnosis, symptoms, and exacerbation history. Adjusted mean direct costs at baseline and follow-up were obtained through generalized estimating equation model. Results: Inflation adjusted mean annual direct costs increased by 5 % (non-significant). Besides direct costs at baseline, higher baseline COPD grades, a history of severe exacerbations in the previous 12 months and comorbidity count >3 were significantly associated with higher total direct costs at the follow-up visit. No statistically significant effects were found for smoking status, years since COPD diagnosis and symptoms (with the exception of dyspnea). Adjusted mean direct costs increased between baseline and follow-up (except in the case of GOLD grade 4). Nevertheless, selective drop out may have led to an underestimation of cost increase. Conclusions: Our findings underline the importance of managing symptoms, exacerbations and comorbidities in the treatment of COPD patients to control the development of direct healthcare costs of COPD over time.","PeriodicalId":243267,"journal":{"name":"Ethics and Economics","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125776942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Determination of Attitudes of Turkish Thoracic Society Members on Exposure to Sexist Approach and Sexism in Business Life 土耳其胸科协会成员对商业生活中性别歧视接触态度的决定

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3164

Birsen Ocaklı, A. Yorgancioglu, F. Topcu, N. Kokturk, H. Altınöz, Y. Yasin, İlknur Genc Kuzuca, Serap Duru, Elif Yildirim, T. Sevim, Serpil Tekgul, E. Tunçay, S. Gungor, B. Goktas, Y. Şenol, Can Ozturk, I. Ozmen, C. Taştan, S. Dülger, E. Uzaslan, F. Erboy, E. Aksoy, P. Gulhan, A. Koçabas, B. Gemicioğlu, S. Topçu, G. Altinisik, P. Çelik

引用次数: 0

Training on the Practical approach to Lung Health- 3 years experience in the Republic of Macedonia 肺部健康实用方法培训——马其顿共和国3年经验

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3167

Biljana Ilievska Poposka, M. Zakoska

引用次数: 0

Patient views on payment for trial participation 患者对参与试验费用的看法

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3163

R. Dobra, T. Higgins, K. Huband, E. Guilmant, S. Fleming

引用次数: 0

Patient preference for COPD treatment inhalers: A Discrete Choice Experiment (DCE) in France – Results of a Pilot Study 患者对COPD治疗吸入器的偏好:法国的离散选择实验(DCE) -一项试点研究的结果

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3156

C. Chouaid, N. Germain, G. Pouvourville, S. Aballéa, D. Korchagina, M. Baldwin, K. Lay, L. Luciani, P. Devillier

{"title":"Patient preference for COPD treatment inhalers: A Discrete Choice Experiment (DCE) in France – Results of a Pilot Study","authors":"C. Chouaid, N. Germain, G. Pouvourville, S. Aballéa, D. Korchagina, M. Baldwin, K. Lay, L. Luciani, P. Devillier","doi":"10.1183/13993003.CONGRESS-2018.PA3156","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3156","url":null,"abstract":"Introduction: Poor inhaler adherence is a major challenge in chronic obstructive pulmonary disease (COPD), and understanding drivers of inhaler preferences may contribute to adherence and improve long term outcomes. Aims and objective: To identify and quantify preferences for inhaler attributes in French COPD patients, by using DCE methodology. Methods: Attributes were defined from a literature search, expert and patient interviews. An online DCE with COPD patients aged 40-75, using an inhaler for COPD was conducted. The pilot study included scenarios of two fictitious inhalers described according to the attributes. The COPD Assessment Test and 18 questions on diagnosis, treatment and socio-demographic profile were included. A D-efficient design with zero priors was used. Analyses used a conditional logit model with interactions. Results: Seven inhaler attributes were defined: shape, dose insertion, dose preparation, dose release, dose confirmation, dose counter, and reusability. Twenty-one patients completed the pilot phase, and 5 did cognitive debriefing interviews. The mean CAT score was 27.14 (range 17-40). Results show the most valued characteristics to be dose insertion, dose counter and reusability, with a tendency to prefer fewer dose preparation steps, and reusable inhalers with a dose counter. Conclusion: The pilot results suggest that the selected attributes are relevant to COPD patients in France, and should therefore be taken into account by healthcare professionals considering treatment options. In the full online survey, 150 patients with COPD will be included; will confirm which attributes are most valued for French COPD patients.","PeriodicalId":243267,"journal":{"name":"Ethics and Economics","volume":"78 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128331575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Household expenditure for tuberculosis care, its determinants and coping strategies among adults 18 years and older of Karachi, Pakistan. 巴基斯坦卡拉奇18岁及以上成年人结核病护理的家庭支出、决定因素和应对策略。

Ethics and Economics Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3161

S. Razzaq, Aysha Zahidie, Z. Fatmi

引用次数: 1